#United States #New York #Humacyte Inc #Levi Korsinsky #Shareholder Rights

Important Notice for Humacyte, Inc. Shareholders

Investors who hold shares in Humacyte, Inc. (NASDAQ: HUMA) need to be aware of a significant class action securities lawsuit that could impact their rights and potential recoveries. This lawsuit, announced by Levi & Korsinsky, LLP, is aimed at recovering losses for shareholders adversely affected by alleged securities fraud occurring between May 10, 2024, and October 17, 2024.

Class Action Details

The class action is being pursued by those who believe they suffered losses due to misleading statements or concealments by the company’s management. Specifically, it addresses the alleged failure of Humacyte's Durham, North Carolina facilities to meet essential good manufacturing practices. Issues raised include improper quality assurance measures and inadequate microbial testing, which delayed the FDA’s review of crucial biologics license applications. Due to these factors, the company's prospects for FDA approval concerning their acellular tissue-engineered vessels for vascular trauma have been profoundly jeopardized.

The allegations suggest that communications from the company about its operations and business projections were materially misleading and lacked a substantiated basis.

Next Steps for Investors

If you are a Humacyte investor and believe you have incurred losses during the specified period, you must act quickly. You have until January 17, 2025, to request that the Court designate you as a lead plaintiff in this case. Notably, being appointed a lead plaintiff is not a prerequisite to partake in recovery from any potential settlements related to the case.

Participation in this class action involves no out-of-pocket costs for qualified shareholders. If you are a class member, potential compensation is available without any payment obligations.

Why Choose Levi & Korsinsky?

With over two decades of experience in complex securities litigation, Levi & Korsinsky has built a robust reputation for securing substantial recoveries for aggrieved shareholders. Their successful track record has placed them among the top securities litigation firms in the United States, consistently recognized in ISS Securities Class Action Services’ Top 50 Report.

If you wish to understand your rights as a shareholder or learn more about the ongoing class action, Levi & Korsinsky has dedicated resources available for your inquiries. Investors can contact Joseph E. Levi, Esq. via email at [email protected] or call at (212) 363-7500.

Contact Information

For further assistance, you can also explore more about this case and submit inquiries through the firm’s website at www.zlk.com.

Conclusion

As a shareholder in Humacyte, it's imperative to stay informed and proactive regarding your legal rights, especially amid ongoing litigation that may directly affect your investments. Taking timely action can be crucial in safeguarding your interests and potentially recovering losses linked to the alleged misconduct by Humacyte, Inc.’s management.